It is estimated 84% of the worldwide flu production relies on units designed, built, and serviced by Alfa Wassermann Separation Technologies (AWST).

For over 60 years, AWST’s continuous flow zonal ultracentrifuge has been a vital component in global production of the annual influenza vaccine. These systems reliably operate year round yielding a product that results in hundreds of millions of doses of vaccine.

One of the great challenges to producing a SARS-CoV-2 vaccine is the need to produce hundreds of millions of doses. AWST ultracentrifuges address that challenge.

COVID-19 process diagram

Pleomorphic RNA viruses

Diameter = ~120 nm
Density = 1.18 g/mL

Influenza virus

Diameter = ~100 nm
Density = 1.19 g/mL

Both SARS-CoV-2, a coronavirus, and influenza are pleomorphic RNA viruses with similar sizes, shapes, densities, and surface proteins. Viral vaccines generally require forming a suspension. Ultracentrifugation is the standard for purifying and concentrating suspensions.

Our unique ultracentrifugation technology bridges the gap between batch operation and large scale production featuring patented continuous flow operation. Scalability from vaccine development to large scale production is the hallmark of AWST’s technology.

Scalability is rooted in our rotor design used in all AWST systems. During rotation, loaded sample particles separate radially utilizing the relatively simple physical phenomena of sedimentation, and once at rest they can be collected in fractions.

Alfa Wassermann offers standard designs and custom-built units meeting a variety of needs with a global team of factory-trained field service engineers.

COVID-19 process diagram

Scalable Continuous Flow Ultracentrifugation

Promatix 1000

AW Promatix 1000™
Research & Development

Promatix 1000

PKII Ultracentrifuge
Pilot Scale Manafacturing

COVID-19 process diagram

KII Ultracentrifuge
Production Scale Manufacturing

Model Promatix 1000 pKII KII
Rotor Size 230 mLs 400, 800, or 1600 mL 3200, or 8 0 00 mL
Typical Flow 0.25 2 L/h Up to 15 L/h Up to 6 0 L/hp to 6 0 L/h
Max. Speed 35,000 rpm 40,500 rpm 40,500 rpm
G Forces 90,500 121,200 121,200

Multiple cores are available with dimensional equivalent forces, only the process volume changes. Gradient formation and recovery is linearly scalable for a variety of materials (Sucrose, CsCl, and Iodixanol)

COVID-19 diagram 1
COVID-19 diagram 2

Vaccine Development

Solutions For COVID-19 Vaccine Development

Why choose Alfa Wassermann
for your vaccine development?

The KII, PKII and Promatix 1000™ Ultracentrifuges are used to perform separations and purifications on a continuous or batch basis – with or without density gradients – with a range of techniques, including:

COVID-19 process diagram
cGMP regulatory compliant
Continuous data collection
Improved Process Time
Reliable Performance
Maximize Yield
Process Support
Improved Process Time
Dedicated Service

Additionally, product recovery and process time can be improved with the AWST Automatic Fluid Handler that works in unison with the zonal ultracentrifuge.

Automate critical processes
Improve product yields
Extensibility with spare I/O
Continuous data collection
Standardize procedures
Mobile work station

Contact Us


Our Mission

To be the supplier whose singular purpose is the support of bioprocess and pharmaceutical industries by providing expertise in continuous flow UCF separation applications and now fluid handling solutions.

Contact Us


Alfa Wassermann Inc . 4 Henderson Drive
West Caldwell . NJ 07006 . USA

Telephone +1 800 220 4488
Fax +1 973 276 0383


Alfa Wassermann B.V. Lorentzlaan 5
3401 MX IJsselstein . Netherlands

Telephone +31 348 487 300
Fax +31 348 433 000